New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
08:04 EDTJAZZJazz Pharmaceuticals and Gentium announce Europcean launch of Defitelio
Jazz Pharmaceuticals and Gentium S.p.A., a Jazz Pharmaceuticals company, announced the commencement of the European commercial launch of Defitelio, the first licensed product for the treatment of severe hepatic veno-occlusive disease in patients over one month of age undergoing haematopoietic stem cell transplantation therapy.1 The companies have launched Defitelio in Germany and Austria and expect to continue the launch in 27 additional European countries on a rolling basis during 2014 and 2015.
News For JAZZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2015
09:20 EDTJAZZCelgene patent latest to be challenged by Hayman Capital's Bass
The Coalition For Affordable Drugs, a group linked to Hayman Capital's Kyle Bass, has requested an Inter Partes Review of Claims 110 of U.S. Patent No. 6,045,501 held by Celgene (CELG), according to a USPTO filing. The 501 patent claims methods for delivering a drug, including a teratogenic drug, to a patient while preventing the exposure of a fetus or other contraindicated individuals to the drug. The patent is related to the company's Revlimid drug. BACKGROUND: Previously, the same coalition requested an Inter Partes Review of patents held by Pharmacyclics (PCYC), Acorda Therapeutics (ACOR), Shire (SHPG) and Jazz Pharmaceuticals (JAZZ). On January 7, Reuters reported that Bass planned to take "around 15 pharmaceutical companies with a combined market capitalization of $450B" into an Inter Partes Review for extending patents in questionable ways, citing a presentation made by Bass in Oslo. PRICE ACTION: Shares of Celgene are down 0.5% to $114.92 in pre-market trading.
April 20, 2015
14:32 EDTJAZZPharmacyclics patent for Imbruvica challenged by Hayman Capital's Bass
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use